← Back to Search

DCFPyL PET/CT for Prostate Cancer

Phase 2

Recruiting

Research Sponsored by Hoag Memorial Hospital Presbyterian

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial suggests that PyL, a novel PET tracer, may be more effective than the standard of care imaging for detecting prostate cancer metastases.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Detection of unsuspected metastases in biochemically recurrent prostate cancer

Detection of unsuspected metastases in high risk prostate cancer

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: High risk prostate cancerExperimental Treatment1 Intervention

DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy

Group II: Biochemically recurrent prostate cancerExperimental Treatment1 Intervention

DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.

Do I qualify?Apply below to find out